|
1
|
Waldhauer I and Steinle A: NK cells and
cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nausch N and Cerwenka A: NKG2D ligands in
tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salih HR, Rammensee HG and Steinle A:
Cutting edge: down-regulation of MICA on human tumors by
proteolytic shedding. J Immunol. 169:4098–4102. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salih HR, Goehlsdorf D and Steinle A:
Release of MICB molecules by tumor cells: mechanism and soluble
MICB in sera of cancer patients. Hum Immunol. 67:188–195. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Waldhauer I and Steinle A: Proteolytic
release of soluble UL16-binding protein 2 from tumor cells. Cancer
Res. 66:2520–2526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boutet P, Agüera-González S, Atkinson S,
Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M:
Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme
regulates proteolytic shedding of the MHC class I-related chain B
protein. J Immunol. 182:49–53. 2009.PubMed/NCBI
|
|
7
|
Groh V, Wu J, Yee C and Spies T:
Tumour-derived soluble MIC ligands impair expression of NKG2D and
T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Raffaghello L, Prigione I, Airoldi I,
Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S
and Pistoia V: Downregulation and/or release of NKG2D ligands as
immune evasion strategy of human neuroblastoma. Neoplasia.
6:558–568. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Märten A, von Lilienfeld-Toal M, Büchler
MW and Schmidt J: Soluble MIC is elevated in the serum of patients
with pancreatic carcinoma diminishing γδT cell cytotoxicity. Int J
Cancer. 119:2359–2365. 2006.PubMed/NCBI
|
|
10
|
Yoo CB and Jones PA: Epigenetic therapy of
cancer: past, present and future. Nat Rev Drug Discov. 5:37–50.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kristensen LS, Nielsen HM and Hansen LL:
Epigenetics and cancer treatment. Eur J Pharmacol. 625:131–142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Armeanu S, Bitzer M, Lauer UM, Venturelli
S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, et
al: Natural killer cell-mediated lysis of hepatoma cells via
specific induction of NKG2D ligands by the histone deacetylase
inhibitor sodium valproate. Cancer Res. 65:6321–6329. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmudde M, Braun A, Pende D, Sonnenmann
J, Klier U, Beck JF, Moretta L and Bröker BM: Histone deacetylase
inhibitors sensitize tumour cells for cytotoxic effects of natural
killer cells. Cancer Lett. 272:110–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang C, Wang Y, Zhou Z, Zhang J and Tian
Z: Sodium butyrate upregulates expression of NKG2D ligand MICA/B in
HeLa and HepG2 cell lines and increases their susceptibility to NK
lysis. Cancer Immunol Immunother. 58:1275–1285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Poggi A, Catellani S, Garuti A, Pierri I,
Gobbi M and Zocchi MR: Effective in vivo induction of NKG2D ligands
in acute myeloid leukaemias by all-trans-retinoic acid or sodium
valproate. Leukemia. 23:641–648. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamanegi K, Yamane J, Kobayashi K,
Kato-Kogoe N, Ohyama H, Nakasho K, Yamada N, Hata M, Nishioka T,
Fukunaga S, et al: Sodium valproate, a histone deacetylase
inhibitor, augments the expression of cell-surface NKG2D ligands,
MICA/B, without increasing their soluble forms to enhance
susceptibility of human osteosarcoma cells to NK cell-mediated
cytotoxicity. Oncol Rep. 24:1621–1627. 2010. View Article : Google Scholar
|
|
17
|
Cho HJ, Lee TS, Park JB, Park KK, Choe JY,
Sin DI, Park YY, Moon YS, Lee KG, Yeo JH, et al: Disulfiram
suppresses invasive ability of osteosarcoma cells via the
inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol.
40:1069–1076. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xin ZF, Kim YK and Jung ST: Risedronate
inhibits human osteosarcoma cell invasion. J Exp Clin Cancer Res.
28:1052009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee KH, Choi EY, Kim MK, Kim KO, Jang BI,
Kim SW, Kim SW, Song SK and Kim JR: Inhibition of histone
deacetylase activity down-regulates urokinase plasminogen activator
and matrix metalloproteinase-9 expression in gastric cancer. Mol
Cell Biochem. 343:163–171. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mitmarker EJ, Griff NJ, Grogan RH, Sarkar
R, Kebebew E, Duh QY, Clark OH and Shen WT: Modulation of matrix
metalloproteinase activity in human thyroid cancer cell lines using
demethylating agents and histone deacetylase inhibitors. Surgery.
149:504–511. 2011. View Article : Google Scholar
|
|
21
|
Vinodhkumar R, Song YS, Ravikumar V,
Ramakrishnan G and Devaki T: Depsipeptide a histone deacetylase
inhibitor down regulates levels of matrix metalloproteinases 2 and
9 mRNA and protein expressions in lung cancer cells (A549). Chem
Biol Interact. 165:220–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waldhauer I, Goehlsdorf D, Gieseke F,
Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG
and Steinle A: Tumor-associated MICA is shed by ADAM proteases.
Cancer Res. 68:6368–6376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu G, Atteridge CL, Wang X, Lundgren AD
and Wu JD: The membrane type matrix metalloproteinase MMP14
mediates constitutive shedding of MHC class I chain-related
molecule A independent of a disintegrin and metalloproteinases. J
Immunol. 184:3346–3350. 2010. View Article : Google Scholar : PubMed/NCBI
|
